An observational study in Alzheimer Disease, Mild Cognitive Impairment and Subjective Cognitive Decline, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.
Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 9th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 55–80 · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 50–85 · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 40+
IRCCS San Raffaele
Ages 50–90 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2,000 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 113 across the 4 interventional studies, 80 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
1 of the studies in Alzheimer Disease by IRCCS San Raffaele that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.
2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.
The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.
In light of the possible advent of disease-modifying drugs for Alzheimer's disease (AD), reliable biomarkers have been developed in recent years to define the presence of AD pathology at the brain level. The current biological gold standards are cerebrospinal fluid (CSF) biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) and amyloid-PET. Both methods have excellent diagnostic properties but are costly and invasive, limiting their use outside of highly specialized centers.
Plasma biomarkers (plasma-Abeta40, plasma-Abeta42, plasma-pTau-181, plasma-NfL, plasma-ApoE, plasma-ApoE4, plasma-GFAP, plasma-sTREM2, and other plasma neurodegeneration biomarkers) represent a potentially less invasive and more economically accessible alternative. Recent studies have shown that plasma biomarkers can differentiate AD from other neurodegenerative disorders with accuracy comparable to CSF and PET, detect AD pathology in MCI patients, and predict future development of AD dementia in patients with SCD or MCI. However, more research is needed before their widespread use in clinical practice.
The BLAD study is designed as a monocentric, prospective, observational epidemiological study with an additional procedure (annual blood draw for 5 years) and a diagnostic accuracy sub-study (not device-based).
Patients will be recruited among those attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital during routine clinical practice. All enrolled patients will undergo annual blood sampling for 5 years in addition to standard clinical assessments.
A sub-population of 150 patients who undergo lumbar puncture as part of their routine diagnostic workup will enter the validation sub-study. Only those whose CSF biomarkers confirm a biological diagnosis of Alzheimer's disease will continue follow-up; others will exit the sub-study.
The equipment for plasma biomarker measurement (CE-marked medical device) and laboratory kits will be provided on free loan by Fujirebio. No clinical or laboratory data will be shared with Fujirebio.
Statistical analyses will include: log-rank test to compare time to AD development between groups above and below the biomarker threshold; linear stepwise regression models, linear mixed-effects models, and multivariable Cox models to assess the prognostic value of plasma biomarkers; longitudinal generalized linear models for repeated measures or Wilcoxon test to assess biomarker dynamics over time. For the validation sub-study, ROC curve analysis will be performed to assess accuracy, sensitivity, and specificity of plasma biomarkers against CSF gold standard.
Adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy, presenting with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature.
Inclusion Criteria (main study and sub-study):
(MMSE) score greater than or equal to 18.
Additional inclusion criterion for the validation sub-study:
Exclusion Criteria (main study):
Exclusion Criteria (validation sub-study):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2000 adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature. All patients undergo annual blood sampling for 5 years in addition to standard clinical follow-up.
Procedure: Annual blood draw for plasma biomarker measurement
150 patients from the main cohort who undergo lumbar puncture as part of their routine diagnostic workup and have CSF biomarkers for Alzheimer's disease available within 6 months of blood draw. Only those with CSF biomarkers confirming a biological diagnosis of Alzheimer's disease continue longitudinal follow-up in the sub-study.
Procedure: Annual blood draw for plasma biomarker measurement
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.
Time to progression to all-cause dementia in MCI patients (primary prognostic endpoint)
Time to clinical progression to all-cause dementia in patients with Mild Cognitive Impairment (MCI) at baseline, assessed using multivariable Cox proportional hazards models. For each plasma biomarker, patients are divided into two groups (above/below the median) and compared using the log-rank test (cause-specific hazard). The study has greater than 95% power to detect a Hazard Ratio of 2 and approximately 75-80% power for HR of 1.5.
Time frame: Annually from baseline up to 5 years
Change in MMSE score over time
Change over time in Mini-Mental State Examination (MMSE) score as a measure of cognitive progression. A decrease of 5 or more points is considered clinically significant progression of cognitive impairment due to AD.
Time frame: Annually from baseline up to 5 years
Conversion from MCI to Alzheimer's disease dementia
Rate of clinical conversion from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia over the 5-year follow-up period, assessed at each annual visit.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42/Abeta40 ratio
Change over time in the plasma Abeta42/Abeta40 ratio, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma pTau-181 levels
Change over time in plasma phosphorylated tau 181 (pTau-181) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma NfL levels
Change over time in plasma neurofilament light chain (NfL) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma GFAP levels
Change over time in plasma Glial Fibrillary Acidic Protein (GFAP) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma sTREM2 levels
Change over time in plasma soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma Abeta40 levels
Change over time in plasma beta-amyloid 40 (Abeta40) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42 levels
Change over time in plasma beta-amyloid 42 (Abeta42) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Time frame: Annually from baseline up to 5 years
Diagnostic accuracy of plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma Abeta42/Abeta40 ratio in diagnosing Alzheimer's disease, using CSF biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) as the gold standard. Patients are classified as AD or non-AD based on CSF results. An AUC of at least 0.80 is expected, with greater than 95% power to reject H0: AUC=0.50 at alpha=0.05.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma pTau-181 vs CSF gold standard (sub-study)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma pTau-181 in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma NfL vs CSF gold standard (sub-study)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma NfL in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma GFAP vs CSF gold standard (sub-study)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma GFAP in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta40 vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for Abeta40 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42 vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for Abeta42 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for Abeta42/Abeta40 ratio biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma pTau-181 vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for pTau-181 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma NfL vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for NfL biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma GFAP vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for GFAP biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma sTREM2 vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for sTREM2 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for ApoE biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE4 vs CSF gold standard (sub-study)
Determination of the optimal diagnostic cut-off values for ApoE4 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Time frame: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jun 2032, 104 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 104 months is above that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.